Fibrobiologics, INC 10-K annual reports

FibroBiologics, Inc. filed an amendment to its 2025 Annual Report, providing detailed information on directors, executive compensation, security ownership, and related party transactions.

FibroBiologics, a clinical-stage biotech, reported increased net losses and a going concern doubt for 2025, while advancing its fibroblast-based therapies and addressing Nasdaq listing compliance.

FibroBiologics details its authorized capital stock, ongoing clinical programs, and potential risks in its annual report on Form 10-K.

FibroBiologics, Inc.'s 10-K filing outlines its capital structure, including common and preferred stock, and details the regulatory environment for its cell therapy product candidates.